Emergent’s Statement on Today’s Office of National Drug Control Policy’s 2024 Opioid Overdose Reversal Medication (OORM) Manufacturers Meeting

We applaud the Biden Administration’s efforts to save lives and mitigate the devastation caused by America’s opioid overdose crisis. We pledge our support to help raise awareness of the risks associated with opioids, including synthetic opioids like fentanyl, to educate Americans on how they could help save a life, and to ensure NARCAN^® Nasal Spray is widely available.

Since the FDA approval in 2015, more than 64 million doses of NARCAN^® Nasal Spray have been distributed across the U.S. and Canada, including ~22 million doses (~11 million two-dose boxes) in 2023 alone.

As referenced during the White House meeting, and have made making the life-saving treatment widely available a priority. To that end, we have advocated for myriad policies to increase access to naloxone, such as standing orders, co-prescription laws and making naloxone available over the counter.

We have also invested in critical educational resources and campaigns like Ready to Rescue, to highlight the risks associated with opioid use and overdose, sharing information on where to get naloxone, and how to use NARCAN^® Nasal Spray should an individual encounter someone in crisis.

Curbing America’s opioid crisis requires a holistic approach that recognizes its origins and evolution and addresses the current flood of synthetic fentanyl. With tens of millions of doses delivered and years of experience, we stand together with our partners across North America to destigmatize opioid overdoses, protect families, and help save lives.

Recent NARCAN^® Nasal Spray developments:

22 million doses (11 million 2-dose cartons) distributed in 2023, which includes part of the OTC retail launch in August.
Extended the shelf life from 3 years to 4 years.
Production capacity of approximately 36 million doses per year.
Expanded reach into businesses, employers (commercial engagement with National Safety Council).